tbuckley/cabot-search huggingface dataset:
Standardisation of labial salivary gland biopsies in Sjogren's syndrome: importance for the practicing rheumatologist
Authors: Robert I Fox
Journal: Annals of the Rheumatic Diseases (2017)

Although only a small number of rheumatologists participate in clinical trials of Sjogren's syndrome (SS), the majority of rheumatologists need to assess the new criteria for SS in their clinical practice. We need to know how to obtain and evaluate the minor labial salivary gland (LSG) biopsy. We are increasingly asked to make critical therapeutic decisions about treatment of life-threatening clinical situations that might be due to SS, so uniform criteria for correct diagnosis are increasingly important.

Fisher et al 1 present an expert consensus for ‘standardisation of LSG’ histopathology in clinical trials in primary SS in this issue.

Rheumatologists are aware that a ‘new’ consensus criteria between the American College of Rheumatology and European League Against Rheumatism were recently approved.2 However, it is less well recognised that SS diagnosis is now based on a ‘point system’, and that four points are required for diagnosis of SS. 



View this table:

Table 1 
Diagnosis of Sjogren's syndrome (SS) is now based on a weighted basis1 



Thus, the basis for diagnosis and treatment of our most difficult patients, such …
Blue-laser imaging and new-generation narrow-band imaging may both be suitable for the detection of colorectal neoplasms
Authors: Qing-Wei Zhang, La-Mei Teng, Xin-Tian Zhang, Xiao-Bo Li
Journal: Endoscopy (2017)

We read with interest the recent article by Shimoda et al. [1] evaluating the adenoma detection ability of a new advanced endoscopic imaging, named blue-laser imaging (BLI), compared with white-light imaging (WLI). The authors concluded that BLI did not improve the adenoma detection rate but had lower colon adenoma miss rates compared with WLI. However, we have some questions as follows.
Measurement of quality of life in women with breast cancer before and after adjuvant chemotherapy: A structural equation modelling
Authors: J. B. Choudhury, G. Beadle, K. Mengersen
Journal: Journal of Clinical Oncology (2009)

e11513 Background: This study examines breast cancer patients’ individual changes in health related quality of life (HRQOL) measures over time and the relationships between these measures within the framework of Structural equation modeling (SEM). Methods: One hundred and fifty five Australian women with breast cancer were asked to complete the Functional Assessment of Cancer Therapy Breast, Version 4 (FACT-B) pre- and post-chemotherapy as measures of HRQOL. In SEM, growth curve modelling was required for the estimation of individual differences in developmental changes of HRQOL scales over time. A growth mixture model was also used for identifying the cross-group differences in the pattern of changes in a given population over time. Results: Reliability and validity of the FACT-G including the fatigue subscale and breast cancer subscale for evaluating Australian breast cancer patients was determined to be sufficient for research purposes. After adjustment for covariates, two subgroups of women were identified with respect of patterns of response, representing largely increasing and decreasing trends in HRQOL respectively. In the former group, on average 85% of breast cancer women reported changes over time with respect to individual HRQOL measures and 78% reported such changes with respect to combined HRQOL Scores. A small group of women reported changes with respect to HRQOL measures in the decreasing group. The greatest contribution to variation in HRQOL measures was in the breast cancer subscale for both individual and combined scores. Subsequent factor analysis of the breast cancer subscale revealed that with one exception, all items loaded onto three separate factors described as self-esteem, physical and psychological. The latter two improved over time, but self- esteem was largely unchanged. Conclusions: The study presents a technique that allows us to identify potential subgroups of study subjects that experience different trajectories of responses. The results of this study provide greater insight into HRQOL changes over time and can help to plan interventions in a better way, ultimately contributing to improvement in HRQOL of women with breast cancer. No significant financial relationships to disclose.
Abstract B29: Effects of prenatal exposure to cancer treatment: The development of a placental murine xenograft model
Authors: Magali Verheecke, Wout Devlies, Els Hermans, Frédéric Amant
Journal: Clinical Cancer Research (2016)

Abstract The aim of this study was to develop a suitable murine xenograft model to examine the possible effect of drugs or chemotherapeutic agents on the placental tissue. Methods: The test population consisted of 4 examination groups of six immunodefficient nude mice. After the mice were ovariectomised and hormonal stimulated (17b estradiol and progesterone pellets), placental tissue derived from first and third trimester pregnancies was engrafted subcutaneously bilateral in the interscapular fat pad. hCG (human chorionic gonadotrophin) secretion was measured in serum and urine by an enzyme-linked immunosorbent assay (ELISA). To examine the viability and preservation of the placental tissue, factors for proliferation (hCG, Ki67), apoptosis (cleaved caspase-3) and murine angiogenesis (CD31) were evaluated by immunohistochemistry (IHC). The expression level of genes relevant for the angiogenesis (IGF-1, PGF, IGF-2), inflammation (eNOS) and proliferation (Flk-1, Flt-1) was compared by using reverse transcription- quantitative real-time polymerase chain reaction (RT-qPCR). Results: Comparing the placental tissue before and after engraftment, we found preserved structure and histological features. Also, the PCR analysis showed preserved genetic characteristics of the primary engrafted placental tissue. hCG secretion, evaluated by ELISA in the urine and blood, was present for 3 weeks. Conclusion: We created a murine xenograft model with proven stability and preserved structure of the engrafted placental tissue for 3 weeks. This established murine xenograft model will be useful to examine the effect of cancer treatment; moreover, it could serve as a model for other fetal toxicity studies. Citation Format: Magali Verheecke, Wout Devlies, Els Hermans, Frédéric Amant. Effects of prenatal exposure to cancer treatment: The development of a placental murine xenograft model. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B29.
Circadian Rhythms and Chronotherapeutics—Underappreciated Approach to Improving Sleep and Wakefulness in Parkinson Disease
Authors: Birgit Högl
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma
Authors: Shaji K. Kumar, Brian G M Durie, Zhuo Su, Joris Diels, Brian Hutton, Annette Lam, Ito Tetsuro
Journal: Blood (2016)
Questionable diagnostic benefit of the commercially available panel of bee venom components
Authors: L. Arzt, D. Bokanovic, C. Schrautzer, I. Schwarz, K. Laipold, W. Aberer, G. J. Sturm
Journal: Allergy (2017)

Abstract For many years, only the major allergen rA pi m 1 has been available on the Immuno CAP system for routine diagnosis of bee venom ( BV ) allergy. Now, there are five components available, and we aimed to detect the sensitivity and specificity of rA pi m 1, 2, 3, 5, and 10 in BV ‐allergic patients. We further evaluated the sensitivity of rA pi m 1 and 2 of an alternative platform and investigated possible differences in the sensitization profile between monosensitization and clinically relevant double sensitization. Analysis of the whole panel of BV allergens of the CAP system still resulted in a lower sensitivity than analysis of the combination of rA pi m 1 and 2 of the Immulite (71.6% vs 85.8%). Sensitization rate of rA pi m 5 was more than doubled in double‐sensitized patients, while there was no difference for rApi m 2. The benefit of the commercially available panel of BV components is questionable, due to the insufficient sensitivity and still unavailable important cross‐reacting allergens.
Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.
Authors: Grover Bagby, Jane Yates, Shannon McWeeney, Byung Park, Keaney Rathbun, Daniela Pilonetto, Richard Harris, John Wagner, Gerard Pals, See Yan Lau, Christina Harrington, Motomi Mori, Ricardo Pasquini
Journal: Blood (2004)
Abstract CS1-2: CS1-2 Clinical utility of multi-gene testing in metastatic breast cancer
Authors: P Bedard
Journal: Cancer Research (2017)

Abstract The goal of many ongoing precision medicine initiatives is to match patients to targeted treatment(s) based upon the identification of specific driver mutations in their tumors. Although large-scale research projects have elucidated the genomic landscape of breast cancer, they have not provided insight into the clinical utility of genomic testing. Institutional studies of small, targeted sequencing panel-based testing approaches involving patients with advanced, metastatic disease demonstrate that only a small proportion of patients ultimately receive genotype-matched treatment. The reasons for this low treatment matching rate include: institutional and/or geographic barriers to access to genotype-matched clinical trials; patient deterioration after testing results are reported; and the limited range of somatic mutations that are “druggable” with approved or investigational drug therapies. While there are promising signals of activity from early phase clinical trials with novel drug treatments targeting specific genomically defined subpopulations - including AKT1, ERBB2, ESR1 and PIK3CA mutations as well as FGFR1 amplification - and advances in circulating tumor DNA technology may allow for greater integration at the point of care, further evidence is needed before multi-gene testing can be recommended in routine clinical practice. Citation Format: Bedard P. CS1-2 Clinical utility of multi-gene testing in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr CS1-2.
Unrelated Cord Blood Transplantation for the Patients with CML, a Japan Cord Blood Bank Network Analysis.
Authors: Tokiko Nagamura-Inoue, Shunro Kai, Minoko Takahashi, Koji Kato, Keiichi Isoyama, Masatoshi Jinzen, Hiroshi Azuma, Shuichi Taniguchi, Masao Nakabayashi, Shunichi Kato
Journal: Blood (2006)
Video-rate volumetric functional imaging of the brain at synaptic resolution
Authors: Rongwen Lu, Wenzhi Sun, Yajie Liang, Aaron Kerlin, Jens Bierfeld, Johannes D Seelig, Daniel E Wilson, Benjamin Scholl, Boaz Mohar, Masashi Tanimoto, Minoru Koyama, David Fitzpatrick, Michael B Orger, Na Ji
Journal: Nature Neuroscience (2017)
Early Allogeneic Blood Stem Cell Transplantation after Melphalan-Induced Aplasia for Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia - Results of a Retrospective Single Center Analysis
Authors: Kerstin Schaefer-Eckart, Knut Wendelin, Sabine Dressler, Starke Martina, Martin Wilhelm
Journal: Blood (2016)
Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice
Authors: Stuart Goldberg, Mauricette Michallet, Rudiger Hehlmann, Teresa Zyczynski, Aimee Foreman, Brian Calimlim, Ron Paquette, Bengt Simonsson, Carlo Gambacorti, Jorge E. Cortes, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro
Journal: Blood (2016)
Human Leukocyte Antigens of A33, B58 or DR7 Decrease the Treatment-Related Mortality in HLA-Matched Sibling Hematopoietic Stem Cell Transplantation in Association with Heat Shock Protein 70-Hom Polymorphisms.
Authors: Jin Won Kim, So Yeon Oh, Hye Jin Kim, Hyeon Gyu Yi, Kyung-Hun Lee, Ji Young Rhee, Eun-Soon Shin, Cheng Zhe Piao, Inho Kim, Sung-Soo Yoon, Myoung Hee Park, Seonyang Park, Byoung Kook Kim
Journal: Blood (2007)
Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups
Authors: L Riva, C Ronchini, M Bodini, F Lo-Coco, S Lavorgna, T Ottone, G Martinelli, I Iacobucci, C Tarella, A Cignetti, S Volorio, L Bernard, A Russo, G E M Melloni, L Luzi, M Alcalay, G I Dellino, P G Pelicci
Journal: Blood Cancer Journal (2014)

Correction to: Blood Cancer Journal (2013) 3, e147; doi: 10.1038/bcj.2013.46; published online 13 September 2013 Since the publication of this article, the authors have identified an error within Table 2, namely that the AML subgroups listed at the bottom of the table were incorrect. The correct table is shown here.
Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.
Authors: Raphael Itzykson, Sylvain Thépot, Christian Recher, Jacques Delaunay, Bruno Quesnel, Francois Dreyfus, Anne Marfaing Koka, Norbert Vey, Aspasia Stamatoullas, Emmanuel Gyan, Thomas Cluzeau, Philippe Rousselot, Oumedaly Reman, Isabelle Plantier, Jean Pierre Marolleau, Pierre Morel, Eric Wattel, Sorin Visanica, Chahinez Zerhouni, Dominique Bordessoule, Lionel Ades, Pierre Fenaux, Claude Gardin
Journal: Blood (2009)
Loss of Non-Inherited Maternal MHC and Materno-Fetal Transmission of p190 Type BCR-ABL Leukemia.
Authors: Takeshi Isoda, Anthony Ford, Daisuke Tomizawa, Frederik W van Delft, David Gonzalez de Castro, Noriko Mitsuiki, Joannah Score, Tomohiko Taki, Tomohiro Morio, Masatoshi Takagi, Hiroh Saji, Shuki Mizutani, Mel Greaves
Journal: Blood (2009)
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma
Authors: Nicola Amodio, Enrica Romeo, Maria Angelica Stamato, Eugenio Morelli, Mariateresa Fulciniti, Lavinia Raimondi, Marzia Leotta, Maria Teresa Di Martino, Pierosandro Tagliaferri, Nikhil C. Munshi, Pierfrancesco Tassone
Journal: Blood (2015)
Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,
Authors: Geert A Huls, Lieke H. van der Helm, Canan Alhan, P.W. Wijermans, Marinus van Marwijk Kooy, Martijn R. Schaafsma, Bart J Biemond, Aart Beeker, Mels Hoogendoorn, Bastiaan P. van Rees, Okke de Weerdt, Jurgen Wegman, Eduard J Libourel, Sylvia A. Luykx-de Bakker, Monique C. Minnema, Rolf Brouwer, Fransien Croon-de Boer, Matthias Eefting, Kon-Siong G. Jie, Arjan A. van der Loosdrecht, Jan Koedam, Nic J.G.M. Veeger, Edo Vellenga
Journal: Blood (2011)
Graduate Medical Education
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Secreted Mediators of Self-Renewal of Hematopoietic Stem Cells Identified Using Bio-Informatic Analysis of Co-Cultures of HSC and Stromal Cells.
Authors: Baiba Vilne, Rouzanna Istvanffy, Christina Eckl, Franziska Bock, Olivia Prazeres da Costa, Volker Stümpflen, Christian Peschel, Hans-Werner Mewes, Robert A.J. Oostendorp
Journal: Blood (2012)
Abstract P3-17-08: The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients
Authors: HEH Chehade, H Headon, U Wazir, O El Tokhy, A Kasem, K Mokbel
Journal: Cancer Research (2017)

Abstract Background: Ductal carcinoma in situ (DCIS) is the predominant pre-invasive neoplasia of the breast. It was observed that omission of axillary dissection in those with pure DCIS had no adverse effect on survival or recurrence. Therefore, axillary dissection typically does not feature in the management of DCIS. However, it has recently been purported that in some cases of DCIS, the axillary lymph nodes may show evidence of invasive disease. Consequently, there may be a role for sentinel lymph node biopsy (SLNB) in patients with DCIS with a high risk of invasion. Materials and Methods: Systematic literature review identified 48 studies (9803 DCIS patients who underwent SLNB). Separate analyses for patients diagnosed preoperatively by core sampling and patients diagnosed postoperatively by specimen pathology were conducted to determine the percentage of patients with axillary nodal involvement. Patient factors were analysed for associations with risk of nodal involvement. Results: The mean percentage of positive SLNBs was higher in the pre-operative group (5.95% vs. 3.02%; p=0.0201). Meta-regression analysis showed a direct association with tumour size (p=0.0333) and grade(p=0.00839), but not median age nor tumour upstage rate. Conclusions: SLNB should be considered in patients with a pre-operative diagnosis of extensive and/or high-grade DCIS after a careful multidisciplinary discussion in order to identify those patients who have unrecognised axillary spread. Citation Format: Chehade HEH, Headon H, Wazir U, El Tokhy O, Kasem A, Mokbel K. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-17-08.
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
Authors: Charles Herbaux, Jordan Gauthier, Pauline Brice, Elodie Drumez, Loic Ysebaert, Hélène Doyen, Luc Fornecker, Krimo Bouabdallah, Guillaume Manson, Hervé Ghesquières, Reza Tabrizi, Eric Hermet, Julien Lazarovici, Anne Thiebaut-Bertrand, Adrien Chauchet, Hélène Demarquette, Eileen Boyle, Roch Houot, Ibrahim Yakoub-Agha, Franck Morschhauser
Journal: Blood (2017)
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
Authors: Jin-Sung Park, Il-Kug Kim, Sangyeul Han, Intae Park, Chan Kim, Jeomil Bae, Seung Ja Oh, Seungjoo Lee, Jeong Hoon Kim, Dong-Cheol Woo, Yulong He, Hellmut G. Augustin, Injune Kim, Doheon Lee, Gou Young Koh
Journal: Cancer Cell (2017)
MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase
Authors: Guang Yang, Yangsheng Zhou, Xia Liu, Lian Xu, Yang Cao, Christopher J Patterson, Yu-Tzu Tai, Kenneth C. Anderson, Zachary Hunter, Steven P. Treon
Journal: Blood (2012)
Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)
Authors: Eva Sahakian, Jennifer Rock-Klotz, Bijal D. Shah, John Powers, Jennifer L. Cultrera, Susan Deng, David M Woods, Michael Nguyen, Fengdong Cheng, Hongwei Wang, Patricio Perez-Villarroel, Maritza Lienlaf, Tesa Knox, Selina Chen-Kiang, Alejandro Villagra, Jianguo Tao, Javier Pinilla-Ibarz, Simon S Jones, Eduardo M. Sotomayor
Journal: Blood (2012)
Abstract P4-08-03: Mathematical modeling of the unfolded protein response pathway in breast cancer cells
Authors: AN Shajahan-Haq, DM Demas, R Clarke, WT Baumann
Journal: Cancer Research (2017)

Abstract Over 70% of all breast cancers are estrogen receptor positive (ER+) and are treated with endocrine therapies such as aromatase inhibitors or ER-disruptors as part of the standard of care. However, endocrine resistance remains a major clinical challenge for the successful treatment of this disease. ER+ breast cancer cells can escape endocrine therapy-mediated cell death through adaptations in the unfolded protein response (UPR), an evolutionarily conserved cellular stress response pathway that is linked to many other pathways (autophagy, metabolism, anti-oxidant response). To better understand how the UPR pathway promotes endocrine resistance, we built a mathematical model from quantitative measurements of key UPR signaling molecules following treatment of ER+ MCF7 cells (endocrine sensitive, estrogen dependent) with dithiothreitol (DTT). DTT disrupts or prevents protein disulfide bonding and is a potent inducer of the UPR. The same measurements were also made in two MCF7-derived resistant cell lines: LCC1 (sensitive to ER-disruptors, estrogen independent) and LCC9 (resistant to ER-disruptors, estrogen independent). Determining the (minimal) changes to the MCF7 mathematical model needed to adequately capture the data from the resistant cell lines allows us to create specific hypotheses for how the UPR adapts to help produce resistance to endocrine therapies. These hypotheses, in turn, can lead to drug targets for reversing resistance. Citation Format: Shajahan-Haq AN, Demas DM, Clarke R, Baumann WT. Mathematical modeling of the unfolded protein response pathway in breast cancer cells [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-08-03.
Defective Triggering of NK Cells Results in Primary CLL Cells Resistance to Cytotoxicity,
Authors: Caroline Veuillen, Jerome Rey, Rémy Castellano, Florence Orlanducci, Françoise Mallet, Sylvaine Just-Landi, Diane Coso, Vadim Ivanov, Xavier Carcopino, Reda Bouabdallah, Yves Collette, Cyril Fauriat, Daniel Olive, Thérèse Aurran
Journal: Blood (2011)
Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts
Authors: Titilola S. Akingbola, Chinedu Anthony Ezekekwu, Joseph Yaria, Santosh L. Saraf, Lewis L. Hsu, Richard S. Cooper, Victor R. Gordeuk, Bamidele O. Tayo
Journal: Blood (2015)